Novoron Bioscience
Pioneering lipoprotein-receptor drug development to repair damage and degeneration to the brain, spinal cord and beyond.
Pioneering lipoprotein-receptor drug development to repair damage and degeneration to the brain, spinal cord and beyond.
Novoron Bioscience is a pioneering biotechnology company focusing on lipoprotein-receptor drug development to address damage and degeneration in the brain, spinal cord, and beyond. Dedicated to tackling challenging neurological conditions such as multiple sclerosis, spinal cord injury, and Alzheimer's disease, the company has garnered attention with its innovative approach. Established in 2014 and headquartered in the United States, Novoron Bioscience recently secured a significant $9.50M investment in a Seed Round led by Two Bear Capital in 10 December 2022. Positioned at the intersection of biopharma, biotechnology, healthcare, and pharmaceutical industries, this company exhibits immense potential for disrupting the field of neurological therapeutics.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Convertible Note | $125.00K | 1 |
|
31 Aug 2021 |
| Grant | $224.95K | 1 | National Institutes of Health | 27 Jun 2014 |
No recent news or press coverage available for Novoron Bioscience.
We care about your data, and we'd love to use cookies make your experience better.
